Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
59.55
+2.59 (4.55%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 51.51 - 61.75
52 week 51.51 - 140.00
Open 52.38
Vol / Avg. 1.92M/1.14M
Mkt cap 5.28B
P/E     -
Div/yield     -
EPS -3.45
Shares 84.74M
Beta 2.54
Inst. own 80%
May 5, 2016
Q1 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 29, 2016
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 8:30AM EDT - Add to calendar
Feb 11, 2016
Q4 2015 Alnylam Pharmaceuticals Inc Earnings Call
Feb 11, 2016
Q4 2015 Alnylam Pharmaceuticals Inc Earnings Release
Feb 10, 2016
Alnylam Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Feb 9, 2016
Alnylam Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
Jan 11, 2016
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Q&A)
Jan 11, 2016
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 5, 2016
Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Conference
Dec 10, 2015
Alnylam Pharmaceuticals Inc R&D Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -1201.44% -705.83%
Operating margin -1225.16% -720.27%
EBITD margin - -720.27%
Return on average assets - -
Return on average equity - -
Employees 256 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

Michael W. Bonney Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
David-Alexandre Gros Senior Vice President, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
John K. Clarke Director
Age: 61
Bio & Compensation  - Reuters
David E. I. Pyott Director
Age: 62
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters